Clinical Trial Update: Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating capecitabine, tucatinib, and intrathecal trastuzumab for leptomeningeal metastasis/disease in HER2-positive metastatic breast …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Leptomeningeal Disease
• Leptomeningeal Metastasis

Drugs mentioned

• Capecitabine (capecitabine)
• HERCEPTIN (trastuzumab)
• Tukysa (tucatinib)

Snippet

Sponsor: UNICANCER | Conditions: Leptomeningeal Metastasis, Leptomeningeal Disease | Phase 2 | Status: RECRUITING